Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Oncology

Standard of Care Treatment: The Frontline Approach

At a Glance

The frontline treatment for Mantle Cell Lymphoma (MCL) depends on your age, fitness, and cancer biology. Options include intensive chemotherapy with or without a stem cell transplant, lower-intensity regimens, and targeted therapies. Most plans end with rituximab maintenance to prolong remission.

The approach to treating Mantle Cell Lymphoma (MCL) has shifted significantly in recent years. Doctors no longer treat every patient with the same high-intensity regimen. Instead, they use a “pathway” system based on your physical fitness, age, and the specific biology of your cancer cells.

Eligibility for Intensive Therapy Pathways

The first step in planning your treatment is determining if you are a candidate for intensive therapy.

  • Candidates for Intensive Therapy: Generally patients under age 65 or 70 with a high level of physical activity and few other health problems [1][2].
  • Candidates for Lower-Intensity Therapy: Typically older patients or those with medical conditions (like heart or kidney disease) that make high-dose chemotherapy dangerous [2].

Treatment for Intensive Therapy Candidates: The TRIANGLE Revolution

Historically, the standard of care for these patients was intensive chemotherapy followed by an Autologous Stem Cell Transplant (ASCT) and then several years of Rituximab maintenance [3][4].

However, a landmark study called the TRIANGLE trial has challenged the necessity of the transplant [5]. This study found that adding a targeted pill (a BTK inhibitor called ibrutinib) to the initial chemotherapy and continuing it for two years significantly improved survival [5]. Most importantly, the trial suggested that patients who received a BTK inhibitor might be able to skip the stem cell transplant entirely and still achieve excellent results [5].

Note: While the TRIANGLE trial used the drug ibrutinib, its approval for MCL was voluntarily withdrawn in the United States in 2023 due to side effects. Today, US doctors apply the lessons of TRIANGLE using newer, safer BTK inhibitors (like acalabrutinib or zanubrutinib) or they rely on alternative regimens [6].

Important Note on TP53: If your pathology report shows a TP53 mutation, most specialists now recommend avoiding ASCT [7][8]. This is because the mutation makes the cancer resistant to the high-dose chemo used in transplants, and targeted therapies are a much better option [9][8].

Treatment for Lower-Intensity Therapy Candidates: The SHINE Trial

For patients who are older or less physically robust, the standard treatment is often a milder chemotherapy regimen called Bendamustine-Rituximab (BR) or R-CHOP [10].

The SHINE trial investigated adding a BTK inhibitor (ibrutinib) to the BR regimen for older patients [11]. The results showed that adding the pill kept the cancer away for much longer [12]. However, there was a major trade-off: adding the pill did not help patients live longer overall because it increased the risk of serious side effects and infections [13]. Because of these toxicities, the drug ibrutinib is no longer standard for MCL in the US, but your doctor might discuss whether a newer, safer targeted drug is right for you.

The Role of Maintenance

Regardless of which pathway you follow, Rituximab maintenance is a critical part of the frontline standard. It involves receiving an infusion of the antibody drug rituximab every 2 to 3 months, usually for 2 or 3 years after your initial treatment is finished [14][15]. This “maintenance” phase helps keep the immune system active against any remaining cancer cells and significantly extends the time patients stay in remission [4][16].

Read next about Options for Relapsed or Refractory Mantle Cell Lymphoma.

Common questions in this guide

What determines if I need intensive or lower-intensity MCL treatment?
Your doctor will look at your age, overall physical fitness, and other medical conditions. Generally, patients under 65 to 70 who are highly active and have no major health issues receive intensive therapy, while older patients or those with heart or kidney conditions receive lower-intensity regimens.
Do I have to get a stem cell transplant for mantle cell lymphoma?
Not necessarily. While an autologous stem cell transplant (ASCT) used to be standard for fit patients, recent studies like the TRIANGLE trial suggest that adding targeted therapies like BTK inhibitors might allow some patients to safely skip the transplant.
How does a TP53 mutation affect my MCL treatment plan?
If your pathology report shows a TP53 mutation, the cancer is often resistant to high-dose chemotherapy. Because of this, specialists usually recommend avoiding a stem cell transplant and focusing on targeted therapies instead.
Are BTK inhibitors like ibrutinib still used for frontline MCL treatment?
While ibrutinib was used in key clinical trials, it was withdrawn for MCL in the United States due to risks of serious side effects and infections. Doctors today typically apply those trial lessons using newer, safer BTK inhibitors like acalabrutinib or zanubrutinib.
What is rituximab maintenance and why is it important?
Rituximab maintenance involves getting an infusion of an antibody drug every two to three months after your initial treatment is finished. This phase usually lasts for two or three years and helps keep your immune system active against remaining cancer cells to extend your remission.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my age and overall health, am I a candidate for the intensive therapy pathway or the lower-intensity pathway?
  2. 2.In light of the TRIANGLE trial, could I potentially skip the stem cell transplant (ASCT) if we add a BTK inhibitor to my treatment?
  3. 3.Given my TP53 status, would a stem cell transplant actually be effective for me, or should we focus on targeted therapies?
  4. 4.What are the specific risks of infection or heart issues I should watch for if we use a BTK inhibitor?
  5. 5.What is the plan for Rituximab maintenance after my initial rounds of treatment?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    Ibrutinib is a safe and effective therapy for systemic mantle cell lymphoma with central nervous system involvement - a multi-centre case series from the United Kingdom.

    Tucker DL, Naylor G, Kruger A, et al.

    British journal of haematology 2017; (178(2)):327-329 doi:10.1111/bjh.14122.

    PMID: 27197509
  2. 2

    New Directions for Mantle Cell Lymphoma in 2022.

    Kumar A, Eyre TA, Lewis KL, et al.

    American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2022; (42()):1-15 doi:10.1200/EDBK_349509.

    PMID: 35561299
  3. 3

    Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.

    Hermine O, Hoster E, Walewski J, et al.

    Lancet (London, England) 2016; (388(10044)):565-75.

    PMID: 27313086
  4. 4

    Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma.

    Le Gouill S, Thieblemont C, Oberic L, et al.

    The New England journal of medicine 2017; (377(13)):1250-1260 doi:10.1056/NEJMoa1701769.

    PMID: 28953447
  5. 5

    Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network.

    Dreyling M, Doorduijn J, Giné E, et al.

    Lancet (London, England) 2024; (403(10441)):2293-2306 doi:10.1016/S0140-6736(24)00184-3.

    PMID: 38705160
  6. 6

    Treatment of relapsed/refractory MCL.

    Silkenstedt E, Dreyling M

    Blood 2025; (145(7)):673-682 doi:10.1182/blood.2023022353.

    PMID: 39059015
  7. 7

    Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma.

    Eskelund CW, Albertsson-Lindblad A, Kolstad A, et al.

    Haematologica 2018; (103(11)):e541-e543 doi:10.3324/haematol.2018.194399.

    PMID: 29794145
  8. 8

    To consolidate or not to consolidate: the role of autologous stem cell transplantation in MCL.

    Silkenstedt E, Dreyling M

    Hematology. American Society of Hematology. Education Program 2024; (2024(1)):42-47 doi:10.1182/hematology.2024000546.

    PMID: 39644050
  9. 9

    Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in TP53-mutated disease.

    Lew TE, Cliff ERS, Dickinson M, et al.

    Leukemia & lymphoma 2023; (64(11)):1792-1800 doi:10.1080/10428194.2023.2241095.

    PMID: 37531077
  10. 10

    Mantle cell lymphoma treatment options for elderly/unfit patients: A systematic review.

    Alnassfan T, Cox-Pridmore MJ, Taktak A, Till KJ

    EJHaem 2022; (3(1)):276-290 doi:10.1002/jha2.311.

    PMID: 35846186
  11. 11

    Impact of best response to ibrutinib plus Bendamustine and rituximab on PFS in MCL: a secondary analysis of SHINE.

    Mishima Y, Hashimoto D, Ichii M, et al.

    Annals of hematology 2025; (104(9)):4605-4610 doi:10.1007/s00277-025-06569-7.

    PMID: 40940567
  12. 12

    Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.

    Wang ML, Jurczak W, Jerkeman M, et al.

    The New England journal of medicine 2022; (386(26)):2482-2494 doi:10.1056/NEJMoa2201817.

    PMID: 35657079
  13. 13

    Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma.

    Wang M, Salek D, Belada D, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025; (43(20)):2276-2284 doi:10.1200/JCO-25-00690.

    PMID: 40311141
  14. 14

    Rituximab maintenance therapy for mantle cell lymphoma: A systematic review and meta-analysis.

    Hilal T, Wang Z, Almader-Douglas D, et al.

    American journal of hematology 2018; (93(10)):1220-1226 doi:10.1002/ajh.25226.

    PMID: 30033656
  15. 15

    Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial.

    Kluin-Nelemans HC, Hoster E, Hermine O, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020; (38(3)):248-256 doi:10.1200/JCO.19.01294.

    PMID: 31804876
  16. 16

    Clinical outcomes and therapeutic modalities in older Chinese patients with MCL: a multi-center real-world retrospective study.

    Yang Y, Yang P, Zhang W, et al.

    Annals of medicine 2025; (57(1)):2482013 doi:10.1080/07853890.2025.2482013.

    PMID: 40148324

This page provides educational information about frontline treatments for Mantle Cell Lymphoma. It does not replace professional medical advice. Always discuss your specific treatment options, genetic test results, and health status with your oncologist.

Get notified when new evidence is published on Mantle cell lymphoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.